TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-19

Archived explainer. For the current picture see today's BHVN page.

Why Is BIOHAVEN LTD (BHVN) Stock Up Today?

By the Top Tier Newswire AI Desk · November 19, 2026 at 9:56 AM ET · reviewed against 4 wire stories

BIOHAVEN LTD (BHVN) is up +7.52% in the latest session. Our newswire has captured 4 stories on BHVN across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 69/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Biohaven Ltd (BHVN) shares rose 7.52% to $13.87, driven by the presentation of promising Phase 1 clinical data for its experimental drug BHV-1530. The move was further supported by an analyst price target increase from JPMorgan, which raised its target to $35 from $14.

What Happened

Biohaven announced that its novel FGFR3-directed antibody-drug conjugate, BHV-1530, demonstrated clinical activity and confirmed responses in patients with FGFR3-altered urothelial and head and neck cancers. The data was presented in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The company highlighted deep and durable responses in the treated patient population, marking a significant milestone for the program.

In addition to the clinical update, JPMorgan increased its price target for the stock to $35, citing the positive clinical readout. This analyst action coincided with the market reaction to the conference presentation. The stock had previously declined 15.3% over the preceding eight sessions, falling from $15.23 to $12.90, making the recent rebound notable against the short-term downtrend.

What The Data Shows

The stock opened at $13.03, a 1.0% gap from the prior close of $12.90, and reached a session high of $14.04 at 9:55 AM ET. Trading volume totaled 0.3 million shares, which is 0.1 times the three-month daily average. The intraday low was $12.85 at 7:30 AM ET.

Biohaven remains unprofitable with a trailing twelve-month earnings per share of -$3.81 and a market capitalization of $2.0 billion. The stock has a beta of 3.13 and trades within a 52-week range of $8.03 to $18.24. On November 19, 2026, the stock printed nine fresh 52-week highs and one fresh 52-week low.

What To Watch

Market participants will monitor future clinical updates for BHV-1530 and the company’s Graves' disease program. Analyst coverage remains a key factor, with recent price target adjustments from JPMorgan, Morgan Stanley, and Deutsche Bank influencing sentiment.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

BHVN by the numbers

Last: $13.87Session: +7.52%7 sessions: -9.66%Coverage: 4 stories / 3 sourcesAI sentiment: 69/100 (bullish)Mkt cap: $2.0B52w: $8.03 to $18.24
BHVN · Nov 19 session (5-min) · +5.81% vs prior close · updated 6:57 PM ET
$12.81$13.57$14.33prev close $12.90$13.657:00 AM9:52 AM12:45 PM3:37 PM6:30 PM7:00 AM · $12.897:05 AM · $12.907:10 AM · $12.907:15 AM · $12.907:20 AM · $12.907:25 AM · $12.897:30 AM · $12.907:40 AM · $13.107:55 AM · $13.208:05 AM · $13.648:35 AM · $13.238:40 AM · $13.288:45 AM · $13.309:00 AM · $13.209:30 AM · $13.699:35 AM · $13.879:40 AM · $13.479:45 AM · $13.699:50 AM · $13.849:55 AM · $14.0010:00 AM · $13.8610:05 AM · $14.1910:10 AM · $14.2210:15 AM · $14.1110:20 AM · $14.0810:25 AM · $14.1110:30 AM · $13.9810:35 AM · $13.9910:40 AM · $14.0110:45 AM · $13.8710:50 AM · $13.8710:55 AM · $14.1311:00 AM · $14.1011:05 AM · $13.8811:10 AM · $13.9011:15 AM · $13.9011:20 AM · $13.9311:25 AM · $13.9511:30 AM · $13.9511:35 AM · $14.0911:40 AM · $14.2511:45 AM · $14.0711:50 AM · $13.9711:55 AM · $14.0312:00 PM · $13.9912:05 PM · $13.8712:10 PM · $13.8312:15 PM · $13.8712:20 PM · $14.0812:25 PM · $14.1512:30 PM · $14.1012:35 PM · $14.0612:40 PM · $14.0212:45 PM · $13.9912:50 PM · $14.0612:55 PM · $13.951:00 PM · $13.891:05 PM · $13.891:10 PM · $13.841:15 PM · $13.751:20 PM · $13.801:25 PM · $13.761:30 PM · $13.861:35 PM · $13.801:40 PM · $13.861:45 PM · $13.811:50 PM · $13.791:55 PM · $13.742:00 PM · $13.752:05 PM · $13.632:10 PM · $13.652:15 PM · $13.632:20 PM · $13.692:25 PM · $13.692:30 PM · $13.662:35 PM · $13.602:40 PM · $13.592:45 PM · $13.542:50 PM · $13.562:55 PM · $13.573:00 PM · $13.543:05 PM · $13.563:10 PM · $13.523:15 PM · $13.583:20 PM · $13.573:25 PM · $13.563:30 PM · $13.563:35 PM · $13.583:40 PM · $13.683:45 PM · $13.673:50 PM · $13.673:55 PM · $13.684:00 PM · $13.654:10 PM · $13.656:30 PM · $13.65
AI sentiment, last 36h · averaged over 4 stories · 69/100 bullish
AI sentiment 69/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishThe Fly · sentiment 74 · Biohaven price target raised to $35 from $14 at JPMorganThe Fly · 74Biohaven price target raised to $35 from $14 at JPMorganPR Newswire · sentiment 74 · Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026PR Newswire · 74Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clin…The Fly · sentiment 64 · Biohaven’s BHV-1530 shows clinical activity, confirmed responses in cancer studyThe Fly · 64Biohaven’s BHV-1530 shows clinical activity, confirmed responses in cancer studyGuruFocus · sentiment 64 · Biohaven (BHVN) Reports Promising Phase 1 Data for BHV-1530 Targeting FGFR3-Altered CancersGuruFocus · 64Biohaven (BHVN) Reports Promising Phase 1 Data for BHV-1530 Targeting FGFR3-Altered Cancers
1d agoGuruFocusBULLISH 64Product/PR

Biohaven (BHVN) Reports Promising Phase 1 Data for BHV-1530 Targeting FGFR3-Altered Cancers

1d agoThe FlyBULLISH 64Product/PR

Biohaven’s BHV-1530 shows clinical activity, confirmed responses in cancer study

1d agoPR NewswireBULLISH 74Product/PR

Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026

Phase 1 data presented in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain, showed deep and durable responses in patients with FGFR3-altered urothelial cancer (UC) and head and neck squamous cell...

1d agoThe FlyBULLISH 74Analyst

Biohaven price target raised to $35 from $14 at JPMorgan

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on BHVN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier BHVN move explainers: 2026-11-19 · 2026-10-23 · 2026-09-11 · 2026-09-10 · 2026-08-27 · 2026-08-26